Oncotelic Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	247.38	249.28	-4.52	-7.9	5.09	-9.39
Depreciation & Amortization	-	-	-	-	0.01	0.06
Other Amortization	0.3	0.2	0.12	0.3	1.98	1.45
Asset Writedown & Restructuring Costs	-	-	3.2	6.08	-12.84	-
Loss (Gain) From Sale of Investments	-365.35	-365.35	-	-0.01	-	-
Stock-Based Compensation	4.02	2.38	-	-	0.9	1.18
Provision & Write-off of Bad Debts	-	-	-	0	-	-
Other Operating Activities	112.18	112	0.11	0.3	2.6	1.95
Change in Accounts Payable	-0.16	0.11	0.3	-0.05	0.8	0.22
Change in Other Net Operating Assets	0	0	0.05	-0.04	-0	0.08
Operating Cash Flow	-1.56	-1.38	-0.74	-1.32	-1.45	-4.43
Short-Term Debt Issued	-	0.91	0.66	1.41	0.97	3.07
Long-Term Debt Issued	-	0.48	-	-	-	-
Total Debt Issued	1.59	1.39	0.66	1.41	0.97	3.07
Short-Term Debt Repaid	-	-	-	-0.04	-	-0.5
Total Debt Repaid	-0.05	-	-	-0.04	-	-0.5
Net Debt Issued (Repaid)	1.54	1.39	0.66	1.38	0.97	2.56
Issuance of Common Stock	-	-	-	-	0.16	1.97
Other Financing Activities	-	-	-	-0.13	-	-
Financing Cash Flow	1.54	1.39	0.66	1.25	1.13	4.53
Net Cash Flow	-0.02	0	-0.08	-0.07	-0.33	0.09
Cash Interest Paid	0.37	0.37	0.37	0.39	0.4	0.3
Cash Income Tax Paid	0	0	0	0	-	-
Levered Free Cash Flow	-3.16	-1.12	-0.31	-0.58	-3.27	-4.24
Unlevered Free Cash Flow	-2.85	-0.77	0.1	-0.23	-3.39	-4.44
Change in Working Capital	-0.1	0.11	0.35	-0.09	0.8	0.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.